Whitehawk Therapeutics (WHWK) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Yarrow Bioscience (YARW) over the past year, gaining 62.2% versus a loss of 4.6%. Over five years, WHWK leads with a -87.1% price change compared with -98.2% for YARW. Whitehawk Therapeutics is the larger company by market cap ($200.7 million vs $183.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | WHWK | YARW |
|---|---|---|
| Share price | $3.52 | $19.71 |
| Market cap | $200.67M | $183.39M |
| 1-day change | +1.44% | -0.81% |
| YTD return | +45.45% | -32.03% |
| 1-year return | +62.21% | -4.55% |
| 5-year return | -87.06% | -98.19% |
| EPS (TTM) | $-1.14 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $46.95 |
| 52-week low | $1.87 | $16.05 |
| Distance from 52-week high | -35.94% | -58.02% |
| Analyst consensus | buy | none |
| Avg. price target upside | +119.03% | +189.19% |
| Average volume | 367.72K | 85.28K |
| Shares outstanding | 57.01M | 9.30M |
| Employees | 32 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed YARW by 66.8 percentage points over the past year.
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
WHWK vs YARW FAQ
Which is bigger, Whitehawk Therapeutics or Yarrow Bioscience?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $200.67M compared with $183.39M for Yarrow Bioscience (YARW).
Which stock has performed better over the past year, WHWK or YARW?
WHWK returned +62.21% over the past 12 months, compared with -4.55% for YARW (price return, excluding dividends). Past performance does not predict future results.
Are Whitehawk Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.